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Abstract
Introduction: Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by
androgen receptor (AR) expression. We analyzed a group of 58 transcriptionally defined MA tumors and proposed
a new tool to identify these tumors.
Methods: We performed quantitative reverse transcription PCR (qRT-PCR) for ESR1, AR, FOXA1 and AR-related genes,
and immunohistochemistry (IHC) for ER, PR, Human Epidermal Growth Factor Receptor 2 (HER2), CK5/6, CK17, EGFR,
Ki67, AR, FOXA1 and GCDFP15 and we analyzed clinical features.
Results: MA tumors were all characterized by ESR1(-) AR(+) FOXA1(+) and AR-related genes positive mRNA profile.
IHC staining on these tumors showed 93% ER(-), only 58% AR(+) and 90% FOXA1(+). 67% and 57% MA tumors
were HER2(3+) and GCDFP15(+), respectively. Almost all MA tumors (94%) had the IHC signature HER2(3+) or
GCDFP15(+) but none of the 13 control basal-like (BL) tumors did. Clinically, MA tumors were rather aggressive,
with poor prognostic factors.
Conclusion: MA tumors could be better defined by their qRT-PCR-AR profile than by AR IHC. In addition, we found
that HER2 or GCDFP15 protein overexpression is a sensitive and specific tool to differentiate MA from BL in the
context of ER negative tumors. A composite molecular and IHC signature could, therefore, help to identify MA
tumors in daily practice.
Keywords: cancer, breast carcinoma, molecular apocrine, estrogen receptor, HER2, GCDFP15, triple negative, basal-
like
Introduction
Breast cancer is the most common invasive cancer in
women. Sex steroid hormones estrogen and progesterone
are key drivers in the carcinogenesis through their
actions on estrogen receptor alpha (ER) and progesterone
receptor (PR). In daily practice, breast cancer molecular
classification is based on the immunohistochemical
expression of these receptors (ER and PR) and of Human
Epidermal Growth Factor Receptor 2 (HER2), a member
of the epidermal growth factor receptor family. However,
the androgen receptor (AR), another member of the ster-
oid receptor family, is also largely expressed in more than
70% of breast cancers and is now clearly implicated in the
pathogenesis of breast cancer [1]. Although largely co-
expressed with ER, AR can also be overexpressed in ER
(-) breast tumors [2]. The ER(-) tumors represent 30% of
breast cancers and are highly heterogeneous, including at
least basal-like (BL) tumors and part of the HER2 positive
tumors. Yet, among these ER(-) tumors, several teams
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have identified the molecular apocrine breast cancer
(MA) subtype, characterized by AR expression and AR
pathway activation on genome-wide expression analyses,
paradoxical expression of genes known to be ER targets
or expressed in ER(+) tumors and HER2 overexpression
in around 50% of cases [3][4]. The existence of this MA
subgroup suggests a new molecular classification for
breast cancers, including luminal, MA and BL breast can-
cer subgroups [5]. AR overexpression may provide a new
therapeutic target for breast cancer [6], especially in
patients with ER(-) tumors that do not benefit from
endocrine or HER2 targeted therapies. A potential thera-
peutic effect of AR inhibition in MA subtype has already
been shown using in vitro models [4]. However, there is
no clear consensus yet to define the MA subgroup,
except by transcriptomic analysis. An easy and reproduci-
ble method to identify MA breast cancers is needed to
better understand the behavior of these tumors and to
enable their inclusion in specific trials.
Here, we used a molecular apocrine qRT-PCR signature
initially defined on a set of breast cancer samples anno-
tated with their transcriptional profiles. We retrospectively
identified a group of MA tumors based on this signature.
We described their clinical, molecular and pathological
features and we identified a new simplified immunohisto-
chemical and molecular signature leading to an easy to
use and reproducible diagnostic tool for these tumors.
Materials and methods
Patients
In order to identify patients with molecular apocrine
tumors, we proposed a qRT-PCR molecular apocrine
(MA) signature defined by the absence of ESR1 overex-
pression (ER-), AR and FOXA1 overexpression, as well as
overexpression of three of five genes related to the AR
pathway (Agr2, ALCAM, SPDEF, TTF3, UGT2B28A),
according to what was previously described in the litera-
ture [4,5].
To validate this MA signature in the context of ER-
negative tumors, we constituted a validation set of 45
ER-negative samples with available microarray data
(E-MTAB-365, GSE26639) predicted to be molecular
apocrine (32 cases) or basal-like (13 cases) by our pre-
viously published predictor [7]. These validation data are
available in Additional file 1. The qRT-PCR signature dis-
criminated correctly the 32 tumors predicted to be molecu-
lar apocrine by the microarray predictor.
With this validated qRT-PCR signature, we retrospec-
tively screened 502 breast cancer patients treated in St.
Louis Hospital (Paris) between 1996 and 2008 and have fro-
zen samples available for molecular analysis. We identified
58 molecular apocrine tumors and used 13 basal-like
tumors as a control group. Clinical data including age, type
of surgery, type of treatment, occurrence and type of
relapse and current status were obtained from the Breast
Disease Center of the hospital by review of medical charts.
Pathological data including histological type, grade, tumor
size, peritumoral vascular invasion and stage were recorded.
Samples were provided by the biological resource center
after approval of the Saint Louis hospital ethical review
board (Paris, France: agreement n° DC 2009-929), following
the Ethics and Legal national French rules for the patients’
information and consent (ANAES, HAS and INCa).
All patients were informed of the study and did not
oppose it, according to our Institutional Review Board
recommendations.
Molecular analyses
Total RNA was extracted from fresh tumor tissue sections
using phenol/chloroform extraction. After a reverse tran-
scription step (Superscript II reverse transcriptase, Life
Technologies SAS, Saint Aubin, France), we analyzed
ESR1, AR, FOXA1 and AR-related genes (UGT2B28A,
ALCAM, AGR2, SPDEF and TTF3) expression using spe-
cific primers and probes or Gene Expression Assays
(Applied Biosystems Inc., Foster City, CA, USA) (ER [8],
AR (Hs00171172_m1), FOXA1 (Hs00270129_m1),
UGT2B28A (Hs00852540_s1), ALCAM (Hs00233455_m1),
AGR2 (Hs00180702_m1), SPDEF (Hs01026048_m1), TFF3
(Hs00173625_m1) by quantitative real time PCR (qPCR,
Taqman 7500, Applied Biosystems Inc.). We performed
relative quantification using the TATA box binding pro-
tein (TBP) gene as the endogenous control and final
results were expressed as normalized ratios (target gene/
reference gene). AR and FOXA1 were considered as over-
expressed with a relative ratio cut-off at 100. The cut-off
ratios were determined on the histogram of mRNA ratio
distribution on our tumors. We showed a clear bimodal
distribution in all our samples, using the mixture model of
two Gaussian distributions with optimal cut-off at the
intersection of the probability density functions [9]. We
determined ERBB2 (HER2) expression level by qRT-PCR
as previously described [10]. We also analyzed TP53 status
by functional assay in yeast (FASAY ) as originally
described in [11,12] and as described in [13].
After DNA extraction using phenol/chloroform method,
we analysed PIK3CA mutational status (hot spots: E542K,
E545K and H1047R) by allelic discrimination on a LC480
cycler (Roche Diagnostics, Meylan, France) [14].
Immunohistochemistry
We performed the following immunohistochemical stain-
ings: ER (clone 6F11, dilution 1/50, Novocastra Labora-
tories, Neucastle Upon Tyne, UK), PR (clone 312, dilution
1/75, Novocastra), HER2 (clone CB11, dilution 1/250,
Novocastra), Ki-67 (clone Mib 1, dilution 1/100, Dako-
France Les Ulis, France), CK5/6 (clone D5/16 B4, dilution
1/50, Dako), CK17 (clone E3, dilution 1/75, Dako), EGFR
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(clone Dak-H1-WT, dilution 1/20, Dako), AR (clone
AR441, dilution 1/20, Dako), FOXA1 (clone 2F83, dilution
1/500, Abcam, paris, France) and GCDFP15 (clone 23A3,
dilution 1/50, Dako). Evaluation of HER2 immunostaining
was scored according to ASCO guidelines [15,16]. Dual
silver in situ hybridization (Roche Ventana, Tucson Ari-
zona, USA) was used in 4 HER2(2+) cases and the polyclo-
nal anti-HER2 antibody (Dako) was used in another HER2
(2+) case. Cytoplasmic immunostainings for GCDFP15
and for basal cytokeratins were considered positive if at
least 5% of the tumor cells were positive. All other immu-
nostainings were nuclear stainings (ER, PR, FOXA1, AR)
and were considered positive if at least 10% of the tumor
cells were positive. For Ki67 immunostaining, the percen-
tage of positive nuclei was noted.
Statistical analyses
Immunohistochemical protein and mRNA expression
were compared between the two tumor groups using
Fisher’s exact tests. Performance of immunohistochem-
ical signatures to discriminate between apocrine and
basal-like tumors was expressed in terms of sensitivity,
specificity and the area under the receiver operating
characteristics curve (AUC). The survival data, overall
survival (OS) and disease free survival (DFS), were esti-
mated using Kaplan-Meier product-limit estimator.
A tumor signature was developed by using classification
trees (CART algorithm) [17]. Briefly, this method builds
up a tree model to reduce misclassification rates or tree
deviance, with a penalization for the tree complexity. The
CART model was first built up to a maximum tree, then
upward tree pruning through 10-fold cross-validation was
used to cut the tree down [18]. Multiple correspondence
analysis (MCA) was used to graphically display the asso-
ciation between the expressions of the different proteins.
All tests were two-sided and P-values <0.05 were consid-
ered as indicating significant association. Analyses were
performed using the R statistical software version 2.10.1
(The R Foundation for Statistical Computing, Vienna,
Austria) [19], with the package tree for CART analyses
[20].
Results
Clinical description of the group of patients
We constituted a cohort of 58 breast cancers presenting
the qRT-PCR signature of the molecular apocrine sub-
group and we used the 13 basal-like tumors as a control
group. The molecular apocrine group presented a mean
age at diagnosis of 54 years and a majority of patients had
a clinical tumor size larger than 2 cm (T2-T3-T4, 81%).
All but seven patients received chemotherapy (neoadju-
vant 15%, adjuvant 59%, neoadjuvant and adjuvant 14%)
and 28% received trastuzumab (Table 1). Clinical data for
basal-like control tumors are also available in Table 1.
Molecular description of the two groups
We analyzed the two groups for ESR1, ERBB2, AR,
FOXA1 and five AR-related genes expression by qRT-
PCR. Molecular apocrine tumors showed lack of ESR1
expression (ER-), overexpression of AR, FOXA1 (Table 2)
and of three out of five AR-related genes (data not
shown). ERBB2 expression level was positive in 68% of
cases. Conversely, all BL tumors showed lack of ESR1,
FOXA1 and ERBB2 expression and also lack of AR in
11/13 cases (85%) (Table 2).
We assessed mutations in the three hotspots of the
PIK3CA gene (E542K, E545K and H1047R) in both tumor
groups. In the MA group, 11/58 (19%) mutations on
PIK3CA could be detected compared to no mutation case
in the BL group (Table 2) with a majority of H1047R
mutations, located in the catalytic domain of PIK3CA
(exon 20). However, the difference between the two
groups was not statistically significant.
Table 1 Patient and tumor characteristics
Characteristics Molecular
apocrine
No. patients (%)
Basal-like
No. patients
(%)
All patients 58 13
Age at diagnosis (range) 54 y.o.
(32 to 86)
43 y.o.
(27 to 63)
Menopausal status
- premenopausal
- postmenopausal
26 (45)
32 (55)
10 (77)
3 (23)
Clinical tumor size
-T0-T1
-T2-T3-T4
11 (19)
47 (81)
0 (0)
13 (100)
Histology
- Invasive ductal
with Paget disease
with apocrine differentiation
with squamous metaplastic
areas
58 (100)
4 (7)
4 (7)
1 (2)
13 (100)
1 (8)
In situ component 44 (76) 3 (23)
Pathological nodal involvment
-N0
-N1, N2, N3
no axillary dissection
22 (38)
33 (57)
3 (5)
11 (85)
2 (15)
Grading SBR
-G2
-G3
15 (26)
43 (74)
1 (8)
12 (92)
Lymphovascular invasion 28 (48) 1 (8)
Treatments:
Surgery
- lumpectomy
- mastectomy
- no
Chemotherapy (CT)
- neoadjuvant CT
- adjuvant CT
- neoadjuvant and adjuvant
CT
- no
Radiotherapy
Trastuzumab
18 (31)
39 (67)
1 (2)
9 (15)
34 (59)
8 (14)
7 (12)
41 (71)
16 (28)
0 (0)
13 (100)
0 (0)
0 (0)
1 (8)
12 (92)
0 (0)
10 (77)
0 (0)
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Additionally, we analyzed the TP53 functional status by
the FASAY assay and 29/58 (50%) of MA tumors were
p53 nonfunctional compared to 100% of the BL tumors
(Table 2).
Pathological and immunohistochemical description of
the two groups
As shown in Table 1, all MA tumors were ductal invasive
carcinoma, with morphological apocrine differentiation in
four tumors (7%), Paget’s disease in four others (7%) and
in situ component in 44 patients (76%). Tumors were
grade 3 in 43 patients (74%), grade 2 in 15 patients (26%),
and lymphovascular invasions were observed in 28 cases
(48%). Pathological data for the BL tumors are also avail-
able in Table 1.
IHC profiles among the MA tumors are shown in Table
3 and two examples are given in Figure 1. Almost all
tumors were ER(-), PR(-) and 67% were HER2 (+). Among
five HER2(2+) cases, four were ERBB2 amplified as shown
by Silver In Situ Hybridization and one case was found
negative with a second anti-HER2 antibody (polyclonal,
Dako). FOXA1 and AR immunostainings were positive in
90% and 58% of MA tumors, respectively, and 57% were
positive for GCDFP15 with 5% to 90% stained tumor cells
(median 50%). Conversely, the majority of cases were
EGFR(-), CK5/6(-), and CK17(-) and 10/55 (18%) tumors
were below 20% Ki67 staining (median 30% stained cells).
Among the four tumors with morphological apocrine
differentiation, all were ER(-) and GCDFP15(+), two were
HER2(3+), two were AR(+) and three were EGFR(+).
In comparison, all the 13 BL tumors were ER(-) PR(-)
HER2(-), AR(-) and GCDFP15(-). Thirty-one percent of
BL tumors were FOXA1(+), 69% EGFR(+) and 62% were
CK5/6(+) and CK17(+). Two BL tumors (15.4%) were
below the 20% threshold for Ki67 staining (median 50%
stained cells). There was no difference between the two
groups for Ki67 expression (Table 3).
Correlation of molecular and immunohistochemical
markers of the two groups
We compared the two groups of tumors for AR and
FOXA1 expressions at protein and mRNA levels. As men-
tioned, all the MA tumors overexpressed AR and FOXA1
mRNA but only 58% and 90% were positive for AR and
FOXA1 with IHC, respectively.
The relative mRNA AR ratio was strongly positive in all
MA cases (Figure 2), with a higher ratio in AR IHC(+)
group compared to AR IHC(-) tumors (mean ratio of 2,207
and 1,062, respectively). In the BL subgroup of tumors, we
observed a good correlation between AR protein and
mRNA levels, all cases showing weak or negative expression
(mean value 45.4). These data suggest that ARmRNA deter-
mination is more sensitive than AR IHC in MA tumors.
The relative FOXA1 ratio was also positive in all MA
cases whatever the IHC staining (Figure 2), but the mean
FOXA1 ratio was not significantly different in the IHC(+)
and IHC (-) group (mean ratio 660.3 versus 524.3) In the
BL subgroup, lack of FOXA1 expression was concordant
at the mRNA and protein levels but four FOXA1 IHC(+)
tumors could not be detected at the mRNA level.
These results suggest that AR and FOXA1 mRNA signa-
tures could not be transposed directly into protein levels
and that AR IHC and FOXA1 IHC do not correctly iden-
tify the MA subgroup.
Table 2 Molecular characteristics of the MA and BL tumors groups (%)
Molecular apocrine Basal-like P-value
No. patients 58 13
ER expression (mRNA) (pos >20)
-negative
58 (100) 13 (100) >0.99
HER2 expression (mRNA) (pos >7)
-positive
-negative
-nd
38 (68)
18 (32)
2
0 (0)
13 (100)
0
<0.0001
AR expression (mRNA) (pos >100)
-positive
-negative
58 (100)
0 (0)
2 (15)
11 (85)
<0.0001
FOXA1 expression (mRNA) (pos >100)
-positive
-negative
58 (100)
0 (0)
0 (0)
13 (100)
<0.0001
PIK3CA status:
-wild type
-mutated
- exon 9: E542K and E545K
- exon 20: H1047R
47 (81)
11 (19)
1
10
13 (100)
0
0
0
0.20
TP53 status (FASAY test)
-functional
-nonfunctional
29 (50)
29 (50)
0 (0)
13 (100)
0.0005
AR, androgen receptor; BL, basal-like; ER, estrogen receptor; HER2, Human Epidermal Growth Factor Receptor 2; MA, molecular apocrine.
Lehmann-Che et al. Breast Cancer Research 2013, 15:R37
http://breast-cancer-research.com/content/15/3/R37
Page 4 of 11
A B
H&E
HER2
GCDFP15
AR
FOXA1
Figure 1 Histopathological features of two molecular apocrine cases. Both cases show apocrine differentiation on H&E stainings, as well as
positive immunostainings for HER2, GCDFP15 and FOXA1. AR immunostaining is positive in case A but negative in case B. AR, androgen
receptor; HER2, Human Epidermal Growth Factor Receptor 2.
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Definition of an immunohistochemical and molecular
signature of the MA subgroup of tumors
As shown in Table 4, AR IHC positivity, evaluated alone
in a ER(-) setting, had a good specificity (100% (95% CI:
75 to 99)) for MA tumors but a poor sensitivity (58%
(95% CI: 44 to 72)). Combining AR IHC with FOXA1
IHC did not improve the specificity and the sensitivity.
Indeed, the IHC signature ER(-) AR(+) FOXA1(+),
although being the IHC counterpart of the molecular
definition, was found in only 57% of MA tumors.
We then studied how the 58 MA and 13 BL tumors were
distributed according to the following IHC markers: ER,
HER2, GCDFP15 and AR (Figure 3). It appeared on this
figure that “HER2(3+) OR GCDFP15(+)” cases accounted
for 51 out of 54 ER(-) tumors (94%) but was never
observed in BL tumors. This IHC signature “HER2(3+) OR
GCDFP15(+)” had a sensitivity and a specificity for apoc-
rine tumors of 94% and 100%, respectively (Table 4) and is
also shown in a tree diagram displaying the best possible
marker combination to discriminate MA and BL tumors in
the ER negative context (Figure 4). Combining AR gene
expression pathway and this IHC signature seems finally to
be an efficient composite approach to define MA tumors.
Survival analysis of the two groups
In the MA subgroup, after a median follow-up of 94
months (range: 0.8 to 175 months), 33 events (local
recurrence n = 8, contralateral n = 3, distant metastasis
Table 3 Immunohistochemical description of the MA and BL tumors groups (%).
Molecular apocrine Basal-like P-value
No. patients 58 13
ER(-) 54 (93) 13 (100) >0.99
PR(-) 56 (97) 13 (100) >0.99
HER2(3+) 39 (67) 0 (0) <0.0001
GCDFP15(+) 33 (57) 0 (0) <0.0001
AR(+) 33 (58) 0 (0) <0.0001
FOXA1(+) 52 (90) 4 (31) <0.0001
EGFR(-) 40 (70) 4 (31) 0.012
CK5/6(-) 51 (89) 5 (38) 0.0003
CK17(-) 54 (95) 5 (38) <0.0001
Ki67 median (range of % stained cells) 30 (0 to 80) 50 (0 to 90) 0.27
AR, androgen receptor; BL, basal-like; ER, estrogen receptor; HER2, Human Epidermal Growth Factor Receptor 2; MA, molecular apocrine; PR, progesterone
receptor.
Figure 2 Relationship between AR and FOXA1 qRT-PCR and IHC in the MA and BL tumors groups. Positive cut-off ratio is 100. Boxplots
indicate first quartile, median and third quartile. Outliers are indicated by small circles. AR, androgen receptor; BL, basal-like; IHC,
immunohistochemistry; MA, molecular apocrine.
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n = 22), and 21 deaths occurred. Five-year disease free
survival (DFS) and overall survival (OS) were 66%
and 77%, respectively. In the BL subgroup, the median
follow-up was 122 months (range: 28; 195) and five-year
DFS and OS were 79% and 73%, respectively (Figure 5).
No statistical difference was observed between the
two groups (p = 0.35 for DFS and p = 0.22 for OS).
Also, in the MA subgroup, there was no statistically
significant difference in terms of DFS according to
the IHC status AR(+)/AR(-), HER2(3+)/HER2(-) or
GCDFP15(+)/GCDFP15(-) of the tumors (see Additional
file 2).
Discussion
Breast cancers are highly hormone-dependent tumors.
The prominent role of the estrogen and progesterone
receptors as prognostic factors and treatment targets is
well established. Despite the fact that androgen expression
in breast cancer has been known for a long time, interest
for this type of hormone nuclear receptor as a possible
biomarker is more recent. The description of the MA
breast cancer subgroup raises new questions about AR
implication in prognosis or prediction of response to hor-
mone blockade in an ER-negative setting. Moreover, easy
and robust identification of this new tumor subgroup is
needed for proper evaluation. We report here a series of
58 MA breast tumors and compare protein and mRNA
expression of genes included in the transcriptomic MA
signature [4]. We propose a sensitive and specific compo-
site immunohistochemical and molecular diagnostic
signature.
MA tumors were originally described by Farmer et al.
[3] who identified, with microarray data, a new subgroup
of breast tumors which often displayed apocrine morphol-
ogy (five out of six cases), and they, therefore, suggested
that these tumors be called “MA breast carcinomas”. To
date, data have been somewhat confusing regarding the
relationship between MA breast tumors and pathologi-
cally-defined apocrine tumors. On breast tissue sections,
histological apocrine changes are defined by eosinophilic
cytoplasms with fine granularity, large nuclei with occa-
sional large nucleoli and frequent apical snouts [21,22].
The term “apocrine carcinoma”, as defined by microscopi-
cal examination, should be used for neoplasms composed
of at least 90% apocrine type epithelium [23]. These
tumors account for 0.5% to 4% of breast carcinomas and
mostly occur at advanced ages. Their prognosis is similar
to that of other breast carcinomas [24]. In our study, we
Table 4 Sensitivity and specificity of the IHC signatures of MA tumors in ER(-) subgroup.
IHC biomarker Sensitivity (95% CI) Specificity (95% CI) AUC
AR(+) 58% (44 to 72) 100% (75 to 99) 0.792 (0.726 to 0.859)
AR(+) and FOXA1(+) 57% (43 to 71) 100% (75 to 99) 0.787 (0.721 to 0.853)
HER2(3+) or GCDFP15(+) 94% (85 to 99) 100% (75 to 99) 0.972 (0.942 to 0.999)
AR, androgen receptor; ER, estrogen receptor; HER2, Human Epidermal Growth Factor Receptor 2; IHC, immunohistochemistry; MA, molecular apocrine.
AR (+)
AR (-)
Basal-like
Molecular apocrine
11
9
12
6
1
13
2
10
3
3
1
Figure 3 Distribution of the MA and BL tumors according to ER, HER2, GCDFP15 and AR immunostainings. Numbers of tumors in each
subgroup are indicated. AR, androgen receptor; BL, basal-like; ER, estrogen receptor; HER2, Human Epidermal Growth Factor Receptor 2; MA,
molecular apocrine.
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found only four morphological apocrine tumors among
58 MA cases, strongly suggesting that the MA subtype
could in fact be much broader than initially reported by
Farmer et al. [3].
A frequently reported feature of apocrine differentia-
tion, whatever being defined morphologically or molecu-
larly, is a strong androgen receptor expression in an
otherwise ER(-) background. Indeed, although sometimes
HER 2 (-) (+)
N = 29 N = 38 
molecular apocrine
A: 38/38
B: 0/38
GCDFP15 (-) (+)
N = 16 N = 13
molecular apocrine
A: 13/13
B: 0/13
basal-like
A: 3/16
B: 13/16
Figure 4 Classification tree in the 67 ER(-) patients. Bold basal-like and molecular apocrine labels refer to the classification result at the
terminal nodes of the tree (leafs). A and B denote the numbers of MA and BL tumor patients over the total number of patients at the nodes.
BL, basal-like; ER, estrogen receptor; MA, molecular apocrine.
Figure 5 DFS and OS curves of the 58 MA and 13 BL tumors. DFS, disease free survival; OS, overall survival.
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reported to belong to several molecular subtypes of
breast cancer [25], morphological apocrine carcinomas
are almost always ER(-) tumors [26] and, among 19
cases, all were ER(-), PR(-) and strongly AR(+) by IHC
[27]. Currently, the MA subgroup is characterized by AR
gene overexpression and Niemeier et al. [28] suggested
that the ER(-)/PR(-)/HER2(+)/AR(+) or ER(-)/PR
(-)/HER2(-)/AR(+) IHC signature could include the “MA
group” described previously by Farmer et al. [3]. How-
ever, our results raise the question whether AR, as
assessed by IHC, is a good marker to define this tumor
subgroup. Indeed, although this marker was pretty speci-
fic for MA carcinomas, since it was absent in BL cancers,
we found that only 58% of MA tumors were IHC AR(+),
thus making this marker not sensitive enough for clinical
use. Conversely, AR mRNA, evaluated by qRT-PCR, was
highly expressed, whatever the level of IHC expression.
Doane et al. [4] also found that only 50% of MA tumors
expressed AR by IHC, despite high AR expression levels in
microarrays data. This dissociation between AR mRNA
and protein expression may be due to a lower sensitivity
of immunohistochemistry or a faster AR degradation due
to activation, leading to undetectable protein.
AR related genes AGR2, ALCAM SPDEF and TTF3 were
found in the top 50 significantly overexpressed genes in
the transcriptomic profiles of MA tumors [4]. Some of
them, like AR itself or SPDEF, have putative androgene
response elements (ARE). Moreover, AGR2 (androgen-
inducible gene anterior gradient-2) is highly induced by
androgen in an androgen receptor (AR)-dependent man-
ner. After all, the main trait of MA tumors is the activa-
tion of the AR pathway, and AR target genes could help to
identify this tumor subgroup.
FOXA1 (Forkhead box protein A1), a member of the
forkhead class of DNA-binding proteins, is a pioneer fac-
tor facilitating the recruitment of ER and AR to their
response elements on the genome. In breast cancer,
FOXA1 expression is highly correlated with ER(+), PR(+)
and endocrine signaling, and may have a prognostic value
in ER(-) tumors [29]. Doane et al. reported that FOXA1 is
overexpressed in the MA subtype [4]. In our study,
according to the transcriptomic definition of our MA
group (ER(-) AR(+) FOXA1(+)), up to 90% of MA tumors
were also FOXA1 positive by IHC. However, 31% of BL
tumors were positive as well, thus making FOXA1 immu-
nostaining not specific enough to identify MA tumors.
GCDFP15, the product of the AR-target gene PIP (Pro-
lactin Induced Protein) [30], has been initially described
as an apocrine marker. It is present at high concentra-
tions in breast cyst fluid [24] but also expressed in ER(+)
or ER(-) breast carcinomas. To date, it is routinely used
for the diagnosis of metastasis of unknown origin to
identify tumors coming from the breast, with 95% specifi-
city and 74% sensitivity [24,31]. GCDFP15 mRNA are
also overexpressed in MA tumors [4]. However, in our
study, GCDFP15 was not more sensitive than AR to iden-
tify MA tumors when analyzed alone by IHC (57% IHC
GCDFP15(+) in the MA group). Our results also showed
that GCDFP15 negativity was constant in BL tumors.
Therefore, in ER(-) tumors, GCDFP15 positive IHC stain-
ing seems to be highly specific of MA cancers but not
very sensitive of this subtype.
We then analyzed the sensitivity and specificity of the
potentially relevant following IHC signatures: AR alone,
AR AND FOXA1, HER2 OR GCDFP15. Doane et al. [4]
also proposed one IHC signature without AR: ER(-) PR(-)
ALCAM(+) and SPDEF(+), but this signature was vali-
dated on only 10 MA tumors. Besides that, ALCAM/
SPDEF immunostainings are not widely used and have not
been standardized so far. Niemeier et al. [28] reported that
the tumors with the IHC profiles ER(-) HER2(3+) AR(+)
or ER(-) HER2(-) AR(+) may be MA tumors but it is likely
that other MA tumors will be missed with this definition
centered on AR IHC. We propose here, in ER(-) breast
tumors, a composite signature including AR gene expres-
sion pathway analysis by qRT-PCR in addition to “HER2(3
+) or GCDFP15(+)” protein expression by IHC. Our IHC
signature is composed of validated immunostainings, with
international guidelines, used on a daily basis in pathology
laboratories. The qRT-PCR profile can be easily obtained
on frozen tissue, provided that a frozen-tissue workflow is
organized. The validation of quantification on formalin-
fixed paraffin-embedded tissues is under way and will
allow qRT-PCR analysis on almost all samples.
We also analyzed other molecular alterations in these
MA tumors. The phosphatidylinositol-3 kinase (PI3K)
signaling pathway is crucial for cell growth and cell survi-
val. Mutations in the gene encoding the p110a (PIK3CA)
subunit of PI3K are commonly found in breast cancer.
Gonzales-Angulo et al. [32] reported a possible association
between the level of AR and PIK3CA mutations. In our
study, although we found PIK3CA mutations only in MA
tumors, the difference was not statistically significant;
however, the number of patients was low. Also, no differ-
ence in AR mRNA expression level could either be
detected in the PIK3CA mutated group of MA tumors
compared to the PIK3CA wild type counterpart (data not
shown).
TP53 mutations are commonly found in ER(-) breast
cancer, and nearly 90% in the triple negative subgroup,
but were present in only 50% of our MA tumors. In
prostate cancer cells, it was described that loss of p53
function contributes to increased AR expression [33]. In
our study, no differences in AR expression could be
detected in the p53 nonfunctional subgroup of MA
tumors compared to the functional p53 group (data not
shown). This potential link between AR and p53 should
be further evaluated.
Lehmann-Che et al. Breast Cancer Research 2013, 15:R37
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In breast cancers, AR is overexpressed in up to 70% of
cases [34], mainly in luminal and low grade tumors
[6,35]. This expression has been associated with a favor-
able outcome in ER(+) tumors [36,37] as well as in ER(-)
tumors [35,38,39]
Little is known about the clinical outcome of MA carci-
nomas, as very few tumors were available in previous tran-
scriptomic studies (six specimens in the works of Farmer
et al. [3], and nine in Doane et al. [4]). In our study
cohort, demographic or clinical presentation did not show
specific features. We did not find any association with
Cowden disease, as reported by some authors [40].
Though limited by small sample size and retrospective
review, we found that MA tumor phenotypes appeared to
be rather aggressive, with a high proportion of poor prog-
nosis factors (grade SBR3, lymphovascular invasion, node
involvement). They were also associated with a poor clini-
cal outcome despite the fact that the wide majority of
patients received chemotherapy.
Recently, Lehmann et al. [41] re-analyzed 21 breast data
sets, including 587 triple negative breast carcinomas
(TNBC), and identified a new TNBC subtype called “lumi-
nal androgen receptor” (LAR) type. Though not named
“molecular apocrine” and all being HER2(-), these 62 LAR
tumors seemed to be included in the MA group. Relapse
free survival was significantly decreased in the LAR sub-
type compared with other TNBC subtypes.
Conclusions
Finally, our study demonstrates that we could accurately
identify MA breast tumors by AR pathway analysis by
qRT-PCR, in addition to HER2 or GCDFP15 protein over-
expression by IHC. This composite tool may be sensitive,
specific and useful to differentiate ER negative tumors in
MA or BL, in daily practice. Accurate identification of MA
tumors could help to include these patients with rather
aggressive tumors in specific “AR-pathway” therapeutic
trials or to identify other therapeutic targets.
Additional material
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to AR, HER2 and GCDFP15 immunostainings.
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